RxDoctor Payments DataLook up a doctor →

Asma Khan, MD

Endocrinology, Diabetes & Metabolism · Chattanooga, TNNPI 1376663294

Payments from drug & device makers

$16,763in general payments, 2019–2025

Across 548 payments — averaging $30.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tandem Diabetes Care, Inc.$7K
  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • Abbott$1K
  • Boehringer Ingelheim$913
  • Medtronic$627
  • plus $5K from 43 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Tandem Diabetes Care, Inc.31$6,637
Novo Nordisk82$1,374
Lilly USA, LLC68$1,118
Abbott41$1,112
Boehringer Ingelheim60$913
Medtronic(2 entities)18$627
Amgen(2 entities)20$400
Sanofi-aventis U.S. LLC21$351
Cequr Corporation3$315
Insulet Corporation17$286
Bayer14$281
Dexcom, Inc.13$279
AstraZeneca(2 entities)18$258
Mannkind Corporation11$241
Ascendis Pharma Endocrinology Inc12$214
Pfizer12$210
Xeris Pharmaceuticals, Inc.13$206
Chiesi USA, Inc.5$174
AbbVie11$166
BETA Bionics, Inc.6$144
Corcept Therapeutics7$137
Neurocrine Biosciences, Inc.4$114
Madrigal Pharmaceuticals4$110
Kyowa Kirin, Inc.5$106
Sequel Med Tech, LLC5$100
Amneal Pharmaceuticals LLC4$91
Merck6$84
Novartis4$82
Radius Health, Inc.3$69
Intuity Medical Inc2$56
Antares Pharma, Inc.3$55
IBSA Pharma Inc.3$50
Amarin Pharma, Inc.3$46
Esperion Therapeutics, Inc.2$39
Boston Scientific2$38
Amryt Pharma Holdings Ltd1$27
Nevro Corp.1$27
Shire North American Group Inc2$26
Baxter Healthcare1$26
Halozyme Inc1$25
Regeneron Healthcare Solutions, Inc.1$21
Rhythm Pharmaceuticals, Inc.1$20
Johnson & Johnson1$19
Evoke Pharma, Inc.1$18
Recordati_rare_diseases_inc.1$17
Intra-sana Laboratories1$16
Aegerion Pharmaceuticals, Inc.1$14
Currax Pharmaceuticals LLC1$14
GSK1$11

How this compares

$16,763 in reported general payments places this provider in the 65th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.

See all endocrinology, diabetes & metabolism providers in Tennessee →

Medicare billing

Part B allowed, 2024
$214,530
Medicare patients
756
Services billed
6,115

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Chattanooga

See the full list for Tennessee →

Where these figures come from

Is this you, or does something look wrong? →